EPANOVA
Clinical safety rating
cautionComprehensive clinical and safety monograph for EPANOVA (EPANOVA).
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
| Metabolism | Epanova (omega-3-carboxylic acids) is hydrolyzed by pancreatic lipase; free fatty acids are absorbed and then metabolized via beta-oxidation similarly to dietary fatty acids. |
| Excretion | Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites. |
| Half-life | Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing. |
| Protein binding | Highly protein bound (>99%), primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution approximately 0.2 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Intramuscular: ~100% (absolute bioavailability not determined in humans due to lack of IV formulation; presumed complete absorption from IM site). |
| Onset of Action | Intramuscular: Clinical effects on serum triglycerides observed within 2 weeks of first dose. |
| Duration of Action | Duration of triglyceride-lowering effect persists for approximately 2 weeks after last dose; sustained with weekly administration. |
| Molecular Weight | 935.8 |
4 g orally once daily as 4 capsules of 1 g each with food.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for renal impairment, including end-stage renal disease on dialysis. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years; no recommended dosing. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to increased risk of adverse effects and comorbidities. Monitor hepatic function closely. |
| 1st trimester | No adequate human data; animal studies show no evidence of harm. Use only if clearly needed. |
| 2nd trimester | No adequate human data; use only if benefit outweighs risk. |
| 3rd trimester | May increase risk of bleeding during delivery due to omega-3 fatty acids; use caution. |
Clinical note
Comprehensive clinical and safety monograph for EPANOVA (EPANOVA).
| Placental transfer | Omega-3 fatty acids cross the placenta; degree of transfer similar to dietary intake. |
| Breastfeeding | Omega-3 fatty acids are normal components of breast milk; supplementation likely safe but data on high doses limited. Monitor infant for potential bleeding risk. |
| Lactation Rating | L2 (probably compatible) |
| Teratogenic Risk | Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the human dose (based on body surface area) did not reveal evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk. |
| Fetal Monitoring | Monitor serum triglycerides periodically during therapy. No specific fetal monitoring required beyond standard routine prenatal care. Monitor for signs of bleeding if anticoagulants are coadministered. |
| Fertility Effects | No studies on fertility effects in humans. In animal studies, oral administration of icosapent ethyl to male and female rats at doses up to 5 times the human dose (based on body surface area) had no effect on fertility or reproductive performance. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to omega-3 fatty acidsGallbladder disease
| Precautions | May increase LDL-C levels; monitor LDL-C during therapy., May prolong bleeding time; use with caution in patients receiving anticoagulants or with bleeding disorders., Risk of atrial fibrillation or flutter in patients with prior cardiovascular disease or diabetes; discontinue if symptoms occur. |
| Food/Dietary | Epanova may be taken with or without food, but taking with a low-fat meal may improve absorption. Avoid high-fat meals as they can increase GI side effects. Grapefruit juice has no known interaction. No significant food restrictions; maintain a heart-healthy diet. |
| Clinical Pearls | For patients with severe hypertriglyceridemia (≥500 mg/dL), Epanova (omega-3 carboxylic acids) reduces triglyceride levels by approximately 25-45% at doses of 2-4 g/day. Absorption is enhanced when taken with a low-fat meal; however, if meals cause GI distress, taking with food is still recommended. Avoid use in patients with known fish allergy. Monitor for atrial fibrillation or flutter, especially in elderly patients or those with cardiovascular risk factors. Dose should be adjusted for renal impairment (eGFR <30 mL/min). |
| Patient Advice | Take Epanova exactly as prescribed, typically 2-4 capsules once daily with food to reduce GI side effects. · Do not break, crush, or chew the capsules; swallow them whole. · Continue a low-fat diet and exercise program while on this medication. · Inform your doctor if you experience symptoms of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing). · Report any irregular heartbeat, chest pain, or shortness of breath immediately. · This medication may increase bleeding risk; tell your doctor if you have a bleeding disorder or take blood thinners (e.g., warfarin). · Store at room temperature away from moisture and heat. |
Loading safety data…